NVO Stock Reality Check: What the Data Says [2026]
Novo Nordisk was briefly the most valuable company in Europe. Then it wasn’t. That 50%+ drawdown from its 2024 peak — while Ozempic is still selling at a pace that would make most pharmaceutical companies weep with envy — is the kind of thing that deserves an honest look, not another hot take. So that’s … Read more